iiinova — where your digital self keeps evolving

Joshua Russo

@jrpcfer.bsky.social

Reposted by Joshua Russo

Dr. Glaucomflecken @glaucomflecken.bsky.social · 13/03/2025

Where does TrumpElon think innovation for all their favorite biotech corporations comes from? PCR only exists because somebody was looking for bacteria in hot springs at Yellowstone. I’m just a private practice ophthalmologist who barely understands p values but even I know this shit is important.

16597139

Reposted by Joshua Russo

Eric Topol @erictopol.bsky.social · 12/03/2025

Maybe the crisis in seabirds with multi-organ failure from exposure to plastics will help raise awareness of their serious hazard and lead to action science.org/doi/10.1126/...

18368102

Reposted by Joshua Russo

Nima Sharifi MD @nimasharifimd.bsky.social · 23/02/2025

About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social

1126

Joshua Russo @jrpcfer.bsky.social · 19/01/2025

Also, this is 1st post on the new platform. Already see alot of familiar faces. Hope the #prostate #cancer #research community continues to grow. 🤞

110

Joshua Russo @jrpcfer.bsky.social · 19/01/2025

Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility. Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏. pubmed.ncbi.nlm.nih.gov/39709604/

pubmed.ncbi.nlm.nih.gov

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer - PubMed

Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We generated...

241